These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 27498157)

  • 1. Integrins in glioblastoma: Still an attractive target?
    Paolillo M; Serra M; Schinelli S
    Pharmacol Res; 2016 Nov; 113(Pt A):55-61. PubMed ID: 27498157
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The role of integrins in glioma biology and anti-glioma therapies.
    Tabatabai G; Tonn JC; Stupp R; Weller M
    Curr Pharm Des; 2011; 17(23):2402-10. PubMed ID: 21827415
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An RGD small-molecule integrin antagonist induces detachment-mediated anoikis in glioma cancer stem cells.
    Paolillo M; Galiazzo MC; Daga A; Ciusani E; Serra M; Colombo L; Schinelli S
    Int J Oncol; 2018 Dec; 53(6):2683-2694. PubMed ID: 30280197
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evolving strategies: future treatment of glioblastoma.
    Chamberlain M
    Expert Rev Neurother; 2011 Apr; 11(4):519-32. PubMed ID: 21469925
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cilengitide treatment for malignant glioma: current status and future direction.
    Kurozumi K; Ichikawa T; Onishi M; Fujii K; Date I
    Neurol Med Chir (Tokyo); 2012; 52(8):539-47. PubMed ID: 22976135
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A New Investigational Perspective for Purines Against Glioblastoma Invasiveness.
    Giuliani P; Zuccarini M; Carluccio M; Ziberi S; Di Iorio P; Caciagli F; Ciccarelli R
    Curr Drug Targets; 2018; 19(16):1871-1881. PubMed ID: 29484991
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Integrin inhibitor cilengitide for the treatment of glioblastoma: a brief overview of current clinical results.
    Scaringi C; Minniti G; Caporello P; Enrici RM
    Anticancer Res; 2012 Oct; 32(10):4213-23. PubMed ID: 23060541
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The aryl hydrocarbon receptor links integrin signaling to the TGF-β pathway.
    Silginer M; Burghardt I; Gramatzki D; Bunse L; Leske H; Rushing EJ; Hao N; Platten M; Weller M; Roth P
    Oncogene; 2016 Jun; 35(25):3260-71. PubMed ID: 26500056
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Periostin (POSTN) Regulates Tumor Resistance to Antiangiogenic Therapy in Glioma Models.
    Park SY; Piao Y; Jeong KJ; Dong J; de Groot JF
    Mol Cancer Ther; 2016 Sep; 15(9):2187-97. PubMed ID: 27307601
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting integrins in malignant glioma.
    Tabatabai G; Weller M; Nabors B; Picard M; Reardon D; Mikkelsen T; Ruegg C; Stupp R
    Target Oncol; 2010 Sep; 5(3):175-81. PubMed ID: 20820929
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A novel treatment for glioblastoma: integrin inhibition.
    Chamberlain MC; Cloughsey T; Reardon DA; Wen PY
    Expert Rev Neurother; 2012 Apr; 12(4):421-35. PubMed ID: 22449214
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [The stem cell niche in glioblastoma: from fundamental aspects to targeted therapies].
    Turpin A; Sharif A; Stoven L; Blond S; Maurage CA; Le Rhun É
    Bull Cancer; 2015 Jan; 102(1):24-33. PubMed ID: 25609493
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combined targeting of adenoviruses to integrins and epidermal growth factor receptors increases gene transfer into primary glioma cells and spheroids.
    Grill J; Van Beusechem VW; Van Der Valk P; Dirven CM; Leonhart A; Pherai DS; Haisma HJ; Pinedo HM; Curiel DT; Gerritsen WR
    Clin Cancer Res; 2001 Mar; 7(3):641-50. PubMed ID: 11297260
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antiangiogenic therapy for high-grade gliomas: current concepts and limitations.
    De Bonis P; Marziali G; Vigo V; Peraio S; Pompucci A; Anile C; Mangiola A
    Expert Rev Neurother; 2013 Nov; 13(11):1263-70. PubMed ID: 24175724
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Peptide-Functionalized Nanoinhibitor Restrains Brain Tumor Growth by Abrogating Mesenchymal-Epithelial Transition Factor (MET) Signaling.
    Wu Y; Fan Q; Zeng F; Zhu J; Chen J; Fan D; Li X; Duan W; Guo Q; Cao Z; Briley-Saebo K; Li C; Tao X
    Nano Lett; 2018 Sep; 18(9):5488-5498. PubMed ID: 30067910
    [TBL] [Abstract][Full Text] [Related]  

  • 16. EMT-like process in glioblastomas and reactive astrocytes.
    Iser IC; Lenz G; Wink MR
    Neurochem Int; 2019 Jan; 122():139-143. PubMed ID: 30496766
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Integrin control of the transforming growth factor-β pathway in glioblastoma.
    Roth P; Silginer M; Goodman SL; Hasenbach K; Thies S; Maurer G; Schraml P; Tabatabai G; Moch H; Tritschler I; Weller M
    Brain; 2013 Feb; 136(Pt 2):564-76. PubMed ID: 23378223
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Activation of hypoxia signaling induces phenotypic transformation of glioma cells: implications for bevacizumab antiangiogenic therapy.
    Xu H; Rahimpour S; Nesvick CL; Zhang X; Ma J; Zhang M; Zhang G; Wang L; Yang C; Hong CS; Germanwala AV; Elder JB; Ray-Chaudhury A; Yao Y; Gilbert MR; Lonser RR; Heiss JD; Brady RO; Mao Y; Qin J; Zhuang Z
    Oncotarget; 2015 May; 6(14):11882-93. PubMed ID: 25957416
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Epithelial-to-Mesenchymal Transition-Like Process in Glioblastoma: An Updated Systematic Review and In Silico Investigation.
    Iser IC; Pereira MB; Lenz G; Wink MR
    Med Res Rev; 2017 Mar; 37(2):271-313. PubMed ID: 27617697
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy of antiangiogenic targeted toxins against glioblastoma multiforme.
    Hall WA; Vallera DA
    Neurosurg Focus; 2006 Apr; 20(4):E23. PubMed ID: 16709029
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.